Gene test picks patients for targeted immunotherapy trial
NCT ID NCT07300891
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called tislelizumab in about 72 adults with advanced solid tumors that no longer respond to standard treatments. Only patients with a specific gene signature (T cell inflamed GEP score) are eligible. The drug is given every three weeks to see if it can shrink tumors or slow disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID CANCER PATIENTS UNEXPOSED TO IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.